IGC Pharma Inc. has released its financial results for the fiscal year ended March 31, 2025. The company's revenue decreased to $1.2 million in Fiscal 2025 from $1.3 million in the previous year, primarily due to the conclusion of infrastructure projects, which generated $164 thousand in revenue in Fiscal 2024 but contributed nothing to the revenue in Fiscal 2025. However, revenue from the Life Sciences segment increased to $1.271 million from $1.181 million, highlighting the company's strategic focus on this area. The company reported a net loss of approximately $7.1 million for Fiscal 2025, an improvement from the $13 million net loss reported in Fiscal 2024. This marks a reduction of about $6 million in net loss year-over-year. In terms of strategic developments, IGC Pharma has made significant clinical progress in Alzheimer's innovation and expanded its strategic initiatives. The company also raised about $4.64 million through private equity placements and an at-the-market offering program during the fiscal year. Additionally, subsequent to the fiscal year-end, the company extended its loan agreement with O-Bank, Co., Ltd. for one year with minor modifications.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.